David Sinclair, Genocea Biosciences co-founder (Alpha Wave Global)
May 24, 2022 11:17 AM EDT
People

Geno­cea reach­es end of road, delist­ing from Nas­daq and let­ting go of re­main­ing staff

Amber Tong

A piv­ot in­to neoanti­gen im­munother­a­pies was not enough to save Geno­cea Bio­sciences af­ter all.

The 16-year-old biotech said it would be clos­ing down and lay­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times